[
  {
    "ts": "2025-09-30T18:49:30+00:00",
    "headline": "What Do Analysts Think About Gilead Sciences (GILD)?",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), keeping the associated price target the same at $143.00. The analyst based the optimistic rating on Gilead Sciences, Inc.’s (NASDAQ:GILD) positive outlook […]",
    "url": "https://finance.yahoo.com/news/analysts-think-gilead-sciences-gild-184930421.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "0b2b5e16-e655-3264-bae9-08e8d77c4d97",
      "content": {
        "id": "0b2b5e16-e655-3264-bae9-08e8d77c4d97",
        "contentType": "STORY",
        "title": "What Do Analysts Think About Gilead Sciences (GILD)?",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), keeping the associated price target the same at $143.00. The analyst based the optimistic rating on Gilead Sciences, Inc.’s (NASDAQ:GILD) positive outlook […]",
        "pubDate": "2025-09-30T18:49:30Z",
        "displayTime": "2025-09-30T18:49:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ha22PhpGlsEhK3tmOzGDVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CkBvnQJGKRIUyIDAWZszGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-gilead-sciences-gild-184930421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-gilead-sciences-gild-184930421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]